Informing Implementation Strategies for Pharmacogenomics in Cancer: Development of Survey Tools for Healthcare Professionals and Consumers

Integration of clinical pharmacogenomics (PGx) within routine cancer care is limited despite frequent use of medicines impacted by PGx, evidence for the benefits of PGx, and the availability of international PGx clinical guidelines. Our study objective was to develop survey tools to assess PGx knowledge, attitudes, practices, perceptions, and education needs among (a) doctors, nurses, and pharmacists involved in cancer care (healthcare professionals, HCPs) and (b) adults who have received cancer treatment or their carers (consumers), with the view to informing implementation strategies for PGx in solid and hematologic cancers. Survey tools were developed in a three-phase (ph) mixed-methods approach. Content was informed by systematic literature review findings and framed by determinants of behavior as informed by the Theoretical Domains Framework (ph-1). Refinement occurred through four separate priority partnership meetings (ph-2). Meetings focused on clinical PGx practices within select cancer streams, and consumers' knowledge, attitudes, and preferences for PGx testing. Content/face validity and health literacy (Flesch Kincaid Grade Level) assessments informed final refinements (ph-3). Separate HCP and consumer survey tools were developed with six common sections: (1) introduction; (2) demographics; (3) experience; (4) knowledge, attitudes, practices and perceptions; (5) education; and (6) vignettes. Content and face validity were rated highly with acceptable health literacy assessments for questions within the consumer survey (median grade level 6; range 1-8). The developed survey tools will be used to generate evidence to inform local implementation strategies for PGx in cancer and promote broader integration of pharmacogenomics in routine clinical care.

Authors

Institutions

Publication Details

Journal
Clinical and Translational Science
Published
2025-03-01
DOI
https://doi.org/10.1111/cts.70144
Citations
1
Primary Topic
Pharmaceutical Practices and Patient Outcomes
Type
article
Field-Weighted Citation Impact
1.22
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Informing Implementation Strategies for Pharmacogenomics in Cancer: Development of Survey Tools for Healthcare Professionals and Consumers

Chiao Xin Lim, David J. M. Routledge, Marliese Alexander, Craig R. Underhill et al.
1 citations
Clinical and Translational Science
Pharmaceutical Practices and Patient Outcomes
1.22
article

Informing Implementation Strategies for Pharmacogenomics in Cancer: Development of Survey Tools for Healthcare Professionals and Consumers

Chiao Xin Lim, David J. M. Routledge, Marliese Alexander, Craig R. Underhill, Amit Khot, Chloe Georgiou, Safeera Hussainy, Sam Harris, Zi-yue Chen, Lindy Leong, Peter Savas, Janine Devine, Ashley Whitechurch, Senthil Lingaratnam, Sarah Glewis, Marcus Samo, Joanne Wickens, Abbey Hird, Gail Rowan, Alistair Bozkurt, Marcus Pergolini, Alysia Kepert
article en
1 citations

Abstract

Integration of clinical pharmacogenomics (PGx) within routine cancer care is limited despite frequent use of medicines impacted by PGx, evidence for the benefits of PGx, and the availability of international PGx clinical guidelines. Our study objective was to develop survey tools to assess PGx knowledge, attitudes, practices, perceptions, and education needs among (a) doctors, nurses, and pharmacists involved in cancer care (healthcare professionals, HCPs) and (b) adults who have received cancer treatment or their carers (consumers), with the view to informing implementation strategies for PGx in solid and hematologic cancers. Survey tools were developed in a three-phase (ph) mixed-methods approach. Content was informed by systematic literature review findings and framed by determinants of behavior as informed by the Theoretical Domains Framework (ph-1). Refinement occurred through four separate priority partnership meetings (ph-2). Meetings focused on clinical PGx practices within select cancer streams, and consumers' knowledge, attitudes, and preferences for PGx testing. Content/face validity and health literacy (Flesch Kincaid Grade Level) assessments informed final refinements (ph-3). Separate HCP and consumer survey tools were developed with six common sections: (1) introduction; (2) demographics; (3) experience; (4) knowledge, attitudes, practices and perceptions; (5) education; and (6) vignettes. Content and face validity were rated highly with acceptable health literacy assessments for questions within the consumer survey (median grade level 6; range 1-8). The developed survey tools will be used to generate evidence to inform local implementation strategies for PGx in cancer and promote broader integration of pharmacogenomics in routine clinical care.

Clinical and Translational ScienceVol. 18(3)
Royal Australian College of General Practitioners (AU), The Royal Melbourne Hospital (AU), The University of Melbourne (AU), Peter MacCallum Cancer Centre (AU), Victorian Comprehensive Cancer Centre (AU), Albury Wodonga Health (AU), Bendigo Health (AU), Monash University (AU), RMIT University (AU)
Quality Education
Openalex Percentile: Top 25%
Pharmaceutical Practices and Patient Outcomes
1.22
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.